Medtronic announced that it has acquired MedinaMedical. The company is based in Menlo Park, Calif., a privately held medical device company that specializes in commercializing the latest technologies for the treatment of cerebrovascular diseases, including cerebral aneurysms. The all-cash acquisition will include an initial payment of $150 million and an additional payment for key milestones. This acquisition is another example of Medtronic's key development strategy for therapeutic innovation. “Medtronics is committed to helping clinicians and patients fight stroke through innovative therapies. MedinaMedical's breakthrough technology is in line with our neurovascular products and will further strengthen our portfolio of hemorrhagic strokes.†Medtronic Recovery Therapy Business Group "The Medina(TM) embolization device uses advanced technology to treat brain aneurysms and will further revolutionize the traditional coil embolization technology in the future," said Brett Wall, president of the neurovascular department. The Medina embolization device (TM) is an intracapsular 3D mesh implant implanted inside the cerebral aneurysm. The technology aims to meet the clinical needs by forming a three-dimensional self-expanding mesh with a distinctive three-dimensional self-expanding mesh structure, conforming to and conforming to the shape of the aneurysm, and reducing blood flow. MedinaMedical CEO Erik Engelson said, "This acquisition gives MedinaMedical a unique opportunity to combine our breakthrough technology with Medtronic's leading clinical, regulatory, market development and commercial expertise. We look forward to working closely with Medtronic to fight the stroke. In particular, aneurysms and hemorrhagic strokes provide economic benefits to our clinical partners and expand coverage." It is reported that cerebral aneurysms are thin-walled spheres formed by the weakening of the cerebral blood wall under the impact of blood flow, which may cause compression of the brain nerves or tissues, or may cause rupture (bleeding). . This technology complements Medtronic's first-class neurological product portfolio. Nearly 6 million people in the United States have cerebral aneurysms (mostly unruptured and undiagnosed). More than 35,000 patients undergo endovascular embolization (including ruptured and unruptured) each year, and 21,000 patients underwent surgical treatment (both ruptured and unruptured). The Medina embolization device has received CE certification from the European Union and is not currently available in the US. The all-cash acquisition will include an initial payment of $150 million and an additional payment for the key milestones. Medtronic has previously invested in MedinaMedical and has ownership stakes prior to the completion of the acquisition of MedinaMedical, which will result in pre-tax earnings for the second quarter of fiscal 2016. Other terms of the acquisition have not been made public. The transaction is expected to meet the long-term financial indicators of Medtronic's acquisition. The MedinaMedical product line will be part of the neurovascular department of the Medtronic Recovery Therapy Group business. Removers,Medical Clip Removers,Medical Clip,Detachable Appliers Qingdao DMD Medical Technology Co., LTD , https://www.conston-tech.com